Skip to main content
    K

    Karyopharm Therapeutics Inc (KPTI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.02
    -0.02 (-56.50%)

    Market Cap: $394,660

    Last updated: Nov 10, 2026 at 7:59 PM ET

    Karyopharm Therapeutics Inc (KPTI) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Karyopharm Therapeutics (KPTI) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Karyopharm Therapeutics reported EPS of -$3.82, below the -$1.05 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(20/40)
    Avg Surprise
    -3.44%

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.62
    Range-$0.83 - -$0.33
    5 analysts
    Revenue Consensus
    $34.65M
    Range$32.49M - $37.03M
    5 analysts

    Next Report

    KPTI has an expected report date of Feb 10, 2027.

    KPTI Earnings Call

    The latest KPTI earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, KPTI beat 20 and missed 20. The widest gap in the table came in the quarter ended Sep 30, 2026, when EPS landed 263.81% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$3.82-$1.05N/A-263.81%MissN/A1N/ANov 5, 2026N/A
    Jun 30, 2026-$2.32-$1.53-$1.68 - -$1.11-51.63%MissN/A30 up, 1 downAug 13, 2026$33.43M
    Mar 31, 2026-$1.24-$1.44-$1.79 - -$0.98+13.89%BeatN/A31 up, 0 downMay 14, 2026$35.07M
    Dec 31, 2025-$2.23-$2.00-$2.25 - -$1.75-11.50%MissN/A20 up, 0 downFeb 12, 2026$34.08M
    Sep 30, 2025-$3.82-$3.25-$3.32 - -$3.18-17.54%MissN/A20 up, 1 downNov 3, 2025$44.04M
    Jun 30, 2025-$4.07-$3.91-$4.72 - -$3.47-4.09%MissN/A51 up, 2 downAug 11, 2025$37.93M
    Mar 31, 2025-$2.77-$3.09-$4.39 - -$0.39+10.36%BeatN/A42 up, 0 downMay 12, 2025$30.02M
    Dec 31, 2024-$3.60-$4.03-$5.25 - -$2.85+10.67%BeatN/A50 up, 2 downFeb 19, 2025$30.54M
    Sep 30, 2024-$3.90-$3.92-$5.10 - -$2.55+0.51%BeatN/A70 up, 0 downNov 5, 2024$38.78M
    Jun 30, 2024-$4.34-$4.47-$4.95 - -$3.00+2.91%BeatN/A71 up, 0 downAug 6, 2024$42.79M
    Mar 31, 2024-$4.80-$4.94-$5.55 - -$4.20+2.83%BeatN/A70 up, 0 downMay 8, 2024$33.13M
    Dec 31, 2023-$0.36-$0.31-$0.36 - -$0.26-16.13%MissN/A70 up, 1 downFeb 29, 2024$33.75M
    Sep 30, 2023-$4.50-$4.29-$4.80 - -$3.45-4.90%MissN/A100 up, 0 downNov 2, 2023$36.01M
    Jun 30, 2023-$4.35-$5.04-$5.85 - -$4.65+13.69%BeatN/A91 up, 1 downAug 2, 2023$37.58M
    Mar 31, 2023-$4.50-$5.23-$7.95 - -$4.65+13.96%BeatN/A91 up, 0 downMay 4, 2023$38.70M
    Dec 31, 2022-$6.45-$5.38-$6.30 - -$3.60-19.89%Miss-193.5%101 up, 0 downFeb 15, 2023$33.58M
    Sep 30, 2022-$6.75-$8.02-$10.94 - -$5.25+15.84%BeatN/A90 up, 0 downNov 3, 2022$36.15M
    Jun 30, 2022-$9.30-$9.55-$12.14 - -$7.50+2.62%BeatN/A90 up, 0 downAug 4, 2022$39.68M
    Mar 31, 2022-$7.95-$9.24-$11.54 - -$6.90+13.96%BeatN/A100 up, 0 downMay 5, 2022$47.67M
    Dec 31, 2021$6.90-$6.37-$12.89 - $6.15+208.32%BeatN/A92 up, 0 downFeb 8, 2022$126.27M
    Sep 30, 2021-$10.35-$10.27-$10.94 - -$8.40-0.78%MissN/A9N/ANov 3, 2021$37.69M
    Jun 30, 2021-$10.65-$10.97-$12.74 - -$9.75+2.92%BeatN/A10N/AAug 5, 2021$22.60M
    Mar 31, 2021-$11.55-$10.75-$11.69 - -$8.25-7.44%MissN/A10N/AMay 3, 2021$23.26M
    Dec 31, 2020-$8.85-$8.97-$11.24 - -$6.60+1.34%BeatN/A10N/AFeb 11, 2021$35.10M
    Sep 30, 2020-$10.95-$10.48-$12.29 - -$8.55-4.48%MissN/A10N/ANov 2, 2020$21.33M
    Jun 30, 2020-$9.45-$8.92-$11.54 - -$7.05-5.94%MissN/A10N/AAug 4, 2020$33.51M
    Mar 31, 2020-$11.70-$10.29-$11.99 - -$8.10-13.70%MissN/A8N/AMay 5, 2020$18.14M
    Dec 31, 2019-$11.40-$10.16-$11.84 - -$9.15-12.20%MissN/A8N/AFeb 13, 2020$18.10M
    Sep 30, 2019-$10.05-$12.17-$13.19 - -$11.09+17.42%BeatN/A8N/ANov 4, 2019$13.15M
    Jun 30, 2019-$10.65-$14.29-$17.24 - -$10.94+25.47%BeatN/A9N/AAug 6, 2019$9.49M
    Mar 31, 2019-$16.35-$12.89-$14.69 - -$8.85-26.84%MissN/A10N/AMay 9, 2019$155000
    Dec 31, 2018-$0.96-$0.85-$1.01 - -$0.53-12.94%MissN/A10N/AFeb 28, 2019N/A
    Sep 30, 2018-$11.85-$13.15-$14.24 - -$11.99+9.89%BeatN/A10N/ANov 8, 2018$478000
    Jun 30, 2018-$9.00-$12.03-$14.39 - -$9.30+25.19%BeatN/A10N/AAug 7, 2018$19.89M
    Mar 31, 2018-$11.70-$9.62-$12.74 - -$2.10-21.62%MissN/A11N/AMay 10, 2018$10.00M
    Dec 31, 2017-$0.80-$0.65-$0.69 - -$0.60-23.08%MissN/A10N/AMar 15, 2018$1.53M
    Sep 30, 2017-$9.75-$9.45-$10.94 - -$9.15-3.17%MissN/A10N/ANov 2, 2017N/A
    Jun 30, 2017-$9.60-$9.77-$12.29 - -$8.40+1.74%BeatN/A11N/AAug 8, 2017$3000
    Mar 31, 2017-$10.65-$9.59N/A-11.05%MissN/AN/AN/AMay 4, 2017$68000
    Dec 31, 2016-$0.65-$0.66N/A+1.52%BeatN/AN/AN/AMar 16, 2017$47000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$12.89, after -$16.64 the year before. It was -$34.85 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$12.89N/A
    Dec 31, 2024-$16.64N/A
    Dec 31, 2023-$13.71N/A
    Dec 31, 2022-$30.45N/A
    Dec 31, 2021-$25.65N/A
    Dec 31, 2020-$40.95N/A
    Dec 31, 2019-$48.45N/A
    Dec 31, 2018-$33.51N/A
    Dec 31, 2017-$30.80N/A
    Dec 31, 2016-$34.85N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,400 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q2Jun 30, 20265,39311
    2026Q1Mar 31, 20266,83513
    2025Q4Dec 31, 20257,83111
    2025Q3Sep 30, 20256,61212
    2025Q2Jun 30, 20257,68712
    2025Q1Mar 31, 20257,09011
    2024Q3Sep 30, 20246,36110

    2026Q2 Earnings Call

    Opening remarks

    Brendan Strong Senior Vice President, Investor Relations Good morning, and thank you all for joining us on today's conference call to discuss Karyopharm's second quarter 2026 financial results and recent company progress. We issued a press release this morning detailing our financial results for the second quarter of 2026. This release, along with the slide presentation that we will reference during our call today, are available on our website. For today's call, as shown on slide 2, I'm joined by Richard, Reshma, Sohanya, and Lori, who will review our second quarter financial results, provide an update on the significant progress we've made advancing our myelofibrosis program, discuss the clinical and regulatory momentum supporting our planned sNDA submission, and review our financial position and capital allocation priorities. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on slide 3. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of our most recent Form 10-Q or 10-K on file with the SEC and in other filings we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any later date. I'll now turn the call over to Richard. Please turn to slide 5.

    Richard Paulson Chief Executive Officer Thank you, Brendan, and good morning, everyone, and thank you for joining us today. The second quarter marked the beginning of an important new chapter for Karyopharm as we advanced selinexor from a compelling and differentiating Phase III data set toward our planned supplemental new drug application under the FDA's Accelerated Approval Pathway for patients with myelofibrosis. Over the past several months, we've remained focused, moved with urgency, and executed against an ambitious plan from generating and presenting the SENTRY data to publishing the results in the Journal of Clinical Oncology to working collaboratively with the FDA to establish a regulatory pathway as we prepare our planned submission. The SENTRY study demonstrated statistically significant, rapid, deep, and sustained spleen responses, together with preliminary overall survival findings and evidence of potential disease modification. These findings have now been presented at leading international scientific meetings, published in a peer-reviewed journal, and continue to generate strong interest globally among the hematology community.

    Frequently Asked Questions About KPTI

    When is Karyopharm Therapeutics's next earnings date?

    Karyopharm Therapeutics's next earnings report is expected for Feb 10, 2027.

    Did KPTI beat earnings estimates last quarter?

    No. Karyopharm Therapeutics reported EPS of -$3.82 for the quarter ended Sep 30, 2026, below the -$1.05 estimate by 263.81%.

    What EPS do analysts expect from KPTI next quarter?

    The consensus EPS estimate for Karyopharm Therapeutics for the quarter ending Dec 31, 2026 is -$0.62 from 5 analysts, with estimates from -$0.83 to -$0.33.

    How often does KPTI beat earnings estimates?

    Karyopharm Therapeutics beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -39.21%.